Zinc monocysteine

单半胱氨酸锌

Report date: 2022/01/14 13:23:58

Base Information

Drug NameZinc monocysteine
Drug Alias NameZ-MonocysZinc monocysteineZinthionein ZCZinthioneinReaZin +[9
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate [NMDA] receptor antagonists
TargetsGlutamate [NMDA] receptor
Therapy Area/IndicationsCognitive DysfunctionCognition DisordersMacular Degeneration +[5
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsCognitive DysfunctionCognition DisordersMacular Degeneration +[5

Other Information

ATC CodeN/A
Related LinksN/A